2[1]Claeys MJ,Bosmans J,De Cenninck M,et al.Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute infarction[J].Am J Cardiol,2004,94(1):9-13.
3[2]Ono H,Osanai T,Ishizaka H,et al.Nicorandil imp roves cardiac function and clinical outcome in patients with acute myocardial infarctien undergoing primary percutaneous coronary intervention:role of inhibitory effect on reactive oxygen species formation[J].Am Heart J,2004,148(4):E15.
4[3]Eeckhout E,Kern MJ.The coronary no-reflow phenomenon:a review of mechanisms and therapies[J].Eur Heart J,2001,22(9):729-739.
5[4]Kloner RA,Ganote CE,Jennings RB.The "no-reflow"phenomenon after temporary coronary occlusian in the dog[J].J Clin Invest,1974,54(6):1496-1508.
6[6]Ambrosio G,Tritto I.Clinical manifestations ef myocardial stunning[J].Comn A rtery Dis,2001,12(5):357-361.
7[7]Kloner RA,Jennings RB.Consequences of brief ischemia:stunning,preconditioning,and their clinical imp lications:part 1[J].Circulation,2001,104(24):2981-2989.
8[8]Kloner RA,Jennings RB.Consequences of brief ischem ia:stunning,p reconditioning,and their clinical imp lications:Part 2[J].Circulation,2001,104(25):3158-3167.
9[9]SolovievA,StefanovA,ParshikovA,et al.Arrhythmogenic peroxynitrite induced alterations in mammalian heart contractility and its prevention with quercetin2filled liposomes[J].Cardiovasc Toxicol,2002,2(2):129-139.
10[10]Kevin LG,Novalija E,Stowe DF.Reactive oxygen species asmediators of cardiac injury and p rotection:the relevance to anesthesia p ractice[J].Anesth Analg,2005,101(5):1275-1287.
10Higgins JPT,Green S. Cochrane handbook for systematic re- views of interventions version 5.1.0 (updated March 2011[EM/OL].The Cochrane Collaboration, 2011. Available from www. cochrane - handbook.org.
